Funding Boost Gets Sunho Biologics Over The IPO Filing Line
Key Takeaways:
With no product or licensing revenue, Sunho Biologics has been piling up debts from high R&D spending
The company only just crept over the listing threshold after a fund-raising round in May boosted its market capitalization
By Molly Wen
